ORIC Pharmaceuticals has filed a patent for a method of treating prostate cancer. The method involves administering a therapeutically effective amount of a glucocorticoid receptor antagonist and an androgen receptor degrader to a subject in need. GlobalData’s report on ORIC Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on ORIC Pharmaceuticals, Peptide pharmacophores was a key innovation area identified from patents. ORIC Pharmaceuticals's grant share as of September 2023 was 24%. Grant share is based on the ratio of number of grants to total number of patents.
Method of treating prostate cancer with gr antagonist and ar degrader
A recently filed patent (Publication Number: US20230302014A1) describes a method for treating prostate cancer in a subject by administering a combination of a glucocorticoid receptor (GR) antagonist and an androgen receptor (AR) degrader. The method is applicable to various types of prostate cancer, including metastatic prostate cancer, metastatic castration-resistant prostate cancer, localized high-risk prostate cancer, recurrent prostate cancer, non-metastatic CRPC (nmCRPC), non-metastatic castration-sensitive prostate cancer, and metastatic castration-sensitive prostate cancer.
The patent claims specify that the GR antagonist can be Compound 1 or a pharmaceutically acceptable salt thereof. Additionally, the GR antagonist can be mifepristone, cyproterone acetate, relacorilant (CORT125134), exicorilant (CORT125281), miricorilant (CORT118335), CORT113176, CORT108297, PT150 (formerly Org34517), PT157, or PT162. On the other hand, the AR degrader can be ARV-110 or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
The patent claims also mention that the GR antagonist and the AR degrader can be administered to the subject concurrently or consecutively, depending on the specific treatment approach. The method aims to target prostate cancer cells that exhibit an elevated expression of the glucocorticoid receptor (GR) prior to the administration of the therapeutic agents.
This patent filing highlights a potential treatment strategy for prostate cancer by combining a GR antagonist and an AR degrader. By targeting both receptors, this method may offer a more comprehensive approach to treating various types of prostate cancer, including metastatic and castration-resistant forms. The specific compounds mentioned in the patent claims provide potential options for the GR antagonist and the AR degrader.
It is important to note that this patent filing does not provide clinical trial data or evidence of the efficacy of this treatment method. Further research and clinical studies would be necessary to validate the effectiveness and safety of this approach. However, the filing of this patent suggests ongoing innovation and exploration in the field of prostate cancer treatment.
To know more about GlobalData’s detailed insights on ORIC Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
